Article
Oncology
Chunmeng Wei, Xi Chen, Jin Ji, Yalong Xu, Xing He, Huiyong Zhang, Zengnan Mo, Fubo Wang
Summary: The study evaluated the performance of urinary exosomal prostate-specific antigen (UE-PSA) in predicting the results of initial prostate biopsies and distinguishing clinically significant prostate cancer. The results showed that UE-PSA had high accuracy and clinical value in predicting and distinguishing prostate cancer, making it a promising noninvasive biomarker to improve prostate cancer detection.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Oncology
Philipp Mandel, Benedikt Hoeh, Felix Preisser, Mike Wenzel, Clara Humke, Maria-Noemi Welte, Inga Jerrentrup, Jens Koellermann, Peter Wild, Derya Tilki, Alexander Haese, Andreas Becker, Frederik C. Roos, Felix K. H. Chun, Luis A. Kluth
Summary: The study revealed a significant positive correlation between preoperative PSA and tumor weight in PCa patients undergoing RP, with an increase in PSA of almost 0.4 ng/ml per 1 g tumor weight. This finding could help estimate tumor burden before RP and in cases of biochemical recurrence.
FRONTIERS IN ONCOLOGY
(2021)
Article
Pathology
Christopher M. Heaphy, Corinne E. Joshu, John R. Barber, Christine Davis, Jiayun Lu, Reza Zarinshenas, Edward Giovannucci, Lorelei A. Mucci, Meir J. Stampfer, Misop Han, Angelo M. De Marzo, Tamara L. Lotan, Elizabeth A. Platz, Alan K. Meeker
Summary: Current biomarkers are insufficient for predicting the prognosis of localized prostate cancer, leading to challenges in treatment decision-making. A study found that the telomere biomarker, which combines variable telomere length in prostate cancer cells and shorter length in prostate cancer-associated stromal cells, is strongly associated with metastasis and prostate cancer death. This biomarker can independently predict outcomes and is robust in surgically treated men.
JOURNAL OF PATHOLOGY CLINICAL RESEARCH
(2022)
Article
Oncology
Danielle S. Bitterman, Ming-Hui Chen, Jing Wu, Andrew A. Renshaw, Marian Loffredo, Philip W. Kantoff, Eric J. Small, Anthony V. D'Amico
Summary: This study found that low testosterone level at PSA failure in high-risk patients with PC treated with RT is associated with increased PCSM and ACM risk, and that higher PSAn is also associated with worse PCSM and ACM risk, especially in men with normal testosterone levels at PSA failure.
Article
Multidisciplinary Sciences
Jae-Uk Jeong, Taek-Keun Nam, Ju-Young Song, Mee Sun Yoon, Sung-Ja Ahn, Woong-Ki Chung, Ick Joon Cho, Yong-Hyub Kim, Shin Haeng Cho, Seung Il Jung, Taek Won Kang, Dong Deuk Kwon
Summary: In patients with locally advanced prostate cancer, the addition of long-term A-ADT over 1 year to radiotherapy leads to favorable biochemical failure-free survival and overall survival rates. Achieving a nadir PSA value <= 0.001 ng/mL is a strong clinical predictor of treatment outcomes for prostate cancer patients receiving combination therapy with radiotherapy and A-ADT.
Article
Cell Biology
Qiang Chen, Xiaorong Yang, Binbin Gong, Wenjie Xie, Ming Ma, Shengqiang Fu, Siyuan Wang, Yutang Liu, Zhicheng Zhang, Ting Sun, Zhilong Li
Summary: The study revealed that SNHG10 is overexpressed in prostate cancer and is associated with advanced clinical parameters, showing significant diagnostic ability. SNHG10 expression is also correlated with oxidative phosphorylation and immune infiltrated cells, affecting cell proliferation, migration, and invasion of PC.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Urology & Nephrology
Patrick-Julien Treacy, Ugo G. Falagario, Francois Magniez, Parita Ratnani, Ethan Wajswol, Alberto Martini, Ivan Jambor, Peter Wiklund, Imad Bentellis, Flora Barthe, Natasha Kyprianou, Matthieu Durand, Daniel Steffens, Sascha Karunaratne, Scott Leslie, Ruban Thanigasalam, Ash Tewari
Summary: This study aimed to evaluate the genomic risk of patients with persistent prostate specific antigen (PSA) using mRNA expression analysis and a validated prognostic genomic-risk classifier. The findings revealed unique genomic features of patients with persistent PSA and confirmed that this condition is associated with a worse prognosis.
MINERVA UROLOGY AND NEPHROLOGY
(2023)
Article
Oncology
Chia-Yang Li, Shu-Pin Huang, Yei-Tsung Chen, Hsin-En Wu, Wei-Chung Cheng, Chao-Yuan Huang, Chia-Cheng Yu, Victor C. Lin, Jiun-Hung Geng, Te-Ling Lu, Bo-Ying Bao
Summary: This study suggests that immunodeficiency pathway-related genes, particularly TNFRSF13B, may play a potential role in the progression of prostate cancer.
CANCER CELL INTERNATIONAL
(2022)
Article
Immunology
Xiaoxiao Cui, Liming Zhang, Guannan Su, Aize Kijlstra, Peizeng Yang
Summary: By analyzing the metabolite composition of sweat in Behcet's disease (BD) patients and healthy controls, a significantly different metabolic profile was observed in BD patients. Potential biomarkers, including l-citrulline, l-pyroglutamic acid, urocanic acid, 2-oxoadipic acid, cholesterol 3-sulfate, and pentadecanoic acid, were identified for further study in BD.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Oncology
Vasiliki Spyratou, Eva Freyhult, Anders Bergh, Camilla Thellenberg-Karlsson, Pernilla Wikstrom, Karin Welen, Andreas Josefsson
Summary: This study investigates the potential of PSA and Ki67 immunoreactive scores as prognostic and treatment-predictive markers for metastatic hormone naive prostate cancer patients. The results show that PSA immunohistochemical score is the strongest prognostic factor for progression-free and overall survival after ADT. Furthermore, a high Ki67/PSA ratio is associated with cell-cycle regulation and DNA damage repair.
Article
Medicine, Research & Experimental
Matteo Bauckneht, Cecilia Marini, Vanessa Cossu, Cristina Campi, Mattia Riondato, Silvia Bruno, Anna Maria Orengo, Francesca Vitale, Sonia Carta, Silvia Chiola, Sabrina Chiesa, Alberto Miceli, Francesca D'Amico, Giuseppe Fornarini, Carlo Terrone, Michele Piana, Silvia Morbelli, Alessio Signori, Paola Barboro, Gianmario Sambuceti
Summary: This study investigated the independent and additive prognostic value of PSMA and FDG gene expression in risk-stratification of prostate cancer (PCa). Machine learning analysis identified a predictive functional network involving glucose metabolism-related genes. Cellular experiments showed that increased proliferation and migration of PCa cells were associated with enhanced FDG uptake and decreased PSMA retention, indicating the prognostic value of FDG PET imaging.
JOURNAL OF TRANSLATIONAL MEDICINE
(2023)
Article
Medicine, Research & Experimental
Jin Song, Shiyong Ma, Lori J. Sokoll, Rodrigo V. Eguez, Naseruddin Hoti, Hui Zhang, Phaedre Mohr, Renu Dua, Dattatraya Patil, Kristen Douglas May, Sierra Williams, Rebecca Arnold, Martin G. Sanda, Daniel W. Chan, Zhen Zhang
Summary: The combination of multiple biomarkers can significantly improve the specificity of detecting aggressive prostate cancer, which is of great significance in addressing the current issue of misdiagnosis and overtreatment.
Article
Urology & Nephrology
Scott A. Greenberg, Samuel L. Washington, Peter E. Lonergan, Janet E. Cowan, Avi S. Baskin, Hao G. Nguyen, Anobel Y. Odisho, Jeffry P. Simko, Peter R. Carroll
Summary: The study found that the presence of benign glandular tissue at the surgical margin after radical prostatectomy was not associated with an increased risk of malignancy at the surgical margin, detectable PSA, biochemical recurrence, or progression after detectable PSA.
JOURNAL OF UROLOGY
(2021)
Review
Oncology
Mohammad Taheri, Sajad Najafi, Abbas Basiri, Bashdar Mahmud Hussen, Aria Baniahmad, Elena Jamali, Soudeh Ghafouri-Fard
Summary: Research on circular RNAs in prostate cancer suggests that they may play a role in promoting the development of the cancer, with some up-regulated circRNAs potentially acting as oncogenes, while down-regulated circRNAs may act as tumor suppressor genes.
FRONTIERS IN ONCOLOGY
(2021)
Review
Urology & Nephrology
Beshara Sheehan, Christina Guo, Antje Neeb, Alec Paschalis, Shahneen Sandhu, Johann S. de Bono
Summary: PSMA is a promising theranostic target in advanced prostate cancer (PCa) and multiple PSMA-targeted therapies have shown antitumour activity. PSMA expression is associated with disease progression, worse clinical outcomes, and DNA damage repair defects. Recent studies have shed light on the complex regulation of PSMA and its interactions with androgen receptor, PI3K/Akt, and DDR signalling. Clinical trials have shown that 177Lu-PSMA-617 can shrink tumours and delay disease progression in metastatic castration-resistant PCa. There are also novel PSMA-targeting immunotherapies, small molecules, and antibody therapies in clinical development.
EUROPEAN UROLOGY FOCUS
(2022)
Article
Pharmacology & Pharmacy
Emilie Henin, Martin Bergstrand, Joseph F. Standing, Mats O. Karlsson
Review
Oncology
R. Almufti, M. Wilbaux, A. Oza, E. Henin, G. Freyer, M. Tod, O. Colomban, B. You
ANNALS OF ONCOLOGY
(2014)
Article
Oncology
B. You, R. Harvey, E. Henin, H. Mitchell, F. Golfier, P. M. Savage, M. Tod, M. Wilbaux, G. Freyer, M. J. Seckl
BRITISH JOURNAL OF CANCER
(2013)
Article
Oncology
M. Wilbaux, E. Henin, A. Oza, O. Colomban, E. Pujade-Lauraine, G. Freyer, M. Tod, B. You
BRITISH JOURNAL OF CANCER
(2014)
Article
Pharmacology & Pharmacy
David Ternant, Guillaume Cartron, Emilie Henin, Michel Tod, Pascal Girard, Gilles Paintaud
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2012)
Article
Pharmacology & Pharmacy
Audrey Lajoinie, Emilie Henin, Behrouz Kassai, David Terry
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2014)
Article
Oncology
Ines Paule, Michel Tod, Emilie Henin, Benoit You, Gilles Freyer, Pascal Girard
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2012)
Article
Oncology
Emilie Henin, Benoit Blanchet, Pascaline Boudou-Rouquette, Audrey Thomas-Schoemann, Gilles Freyer, Michel Vidal, Francois Goldwasser, Michel Tod
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2014)
Article
Pharmacology & Pharmacy
Anne-Charlotte Castellan, Michel Tod, Francois Gueyffier, Melanie Audars, Frederic Cambriels, Behrouz Kassai, Patrice Nony
CLINICAL PHARMACOKINETICS
(2013)
Article
Oncology
Florence Ranchon, Celine Moch, Benoit You, Gilles Salles, Verane Schwiertz, Nicolas Vantard, Emilie Franchon, Claude Dussart, Emilie Henin, Olivier Colomban, Pascal Girard, Gilles Freyer, Catherine Rioufol
EUROPEAN JOURNAL OF CANCER
(2012)
Article
Biochemistry & Molecular Biology
Lorena Martinez, Ophelie Arnaud, Emilie Henin, Houchao Tao, Vincent Chaptal, Rupak Doshi, Thibault Andrieu, Sebastien Dussurgey, Michel Tod, Attilio Di Pietro, Qinghai Zhang, Geoffrey Chang, Pierre Falson
Article
Oncology
Melanie Wilbaux, Emilie Henin, Amit Oza, Olivier Colomban, Eric Pujade-Lauraine, Gilles Freyer, Michel Tod, Benoit You
GYNECOLOGIC ONCOLOGY
(2014)
Article
Pharmacology & Pharmacy
Steve Choy, Emilie Henin, Jan-Stefan van der Walt, Maria C. Kjellsson, Mats O. Karlsson
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
(2013)
Article
Oncology
Alexandre Sostelly, Emilie Henin, Laure Chauvenet, Anne-Claire Hardy-Bessard, Veronique Jestin-Le Tallec, Sylvie Kirsher, Cecile Leyronnas, Catherine Ligeza-Poisson, Soraya Ramdane, Jacques Salavt, Sylvie Van-Hult, Jean-Michel Vannetzel, Gilles Freyer, Michel Tod, Claire Falandry
JOURNAL OF GERIATRIC ONCOLOGY
(2013)
Review
Biotechnology & Applied Microbiology
Salima Hamizi, Gilles Freyer, Naoual Bakrin, Emilie Henin, Amina Mohtaram, Olivia Le Saux, Claire Falandry
ONCOTARGETS AND THERAPY
(2013)